Research Analysts Set Expectations for ACHV FY2028 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Stock analysts at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a research note issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of $0.23 for the year, down from their prior forecast of $0.24. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2029 earnings at $0.97 EPS and FY2030 earnings at $1.47 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.64).

ACHV has been the subject of several other reports. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a research report on Tuesday, June 23rd. Weiss Ratings upgraded shares of Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Wall Street Zen raised shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Raymond James Financial initiated coverage on Achieve Life Sciences in a research note on Friday, June 26th. They set a “strong-buy” rating and a $20.00 price target for the company. Finally, Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the stock a “buy” rating in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $16.00.

Achieve Life Sciences Stock Up 1.5%

Achieve Life Sciences stock opened at $6.77 on Wednesday. Achieve Life Sciences has a 1-year low of $2.37 and a 1-year high of $7.11. The firm has a market capitalization of $695.01 million, a price-to-earnings ratio of -6.04 and a beta of 2.24. The firm’s fifty day moving average price is $6.00 and its two-hundred day moving average price is $4.89. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ACHV. AQR Capital Management LLC purchased a new position in Achieve Life Sciences during the first quarter worth about $32,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences in the 4th quarter valued at about $64,000. Jefferies Financial Group Inc. purchased a new stake in Achieve Life Sciences in the 4th quarter valued at about $84,000. HRT Financial LP bought a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $93,000. Finally, Robertson Stephens Wealth Management LLC lifted its position in shares of Achieve Life Sciences by 100.0% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 10,000 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.